Windlas Biotech Limited — Investor Meet, 29-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Windlas Biotech’s FY25 revenue grew 20.4% to INR759 Cr, with Q4 revenue up 18% YoY to INR202.7 Cr. EBITDA rose 20% to INR94.1 Cr, and PAT reached INR61 Cr. The Generic Formulations CDMO segment grew 15% to INR555 Cr, trade generics surged 41% to INR172 Cr, and exports rose 19% to INR33 Cr. Injectable revenue reached INR6 Cr in Q4, with breakeven expected post-FY26. Oral solids capacity utilization is ~60%, with a new plant set to boost revenue potential to INR1,000 Cr. Management is positive on growth and margin expansion amid client diversification and injectable stability.